Drug intelligence / Profile preview

DUP10

Development stage: Preclinical
Lead developer: Duality Biotherapeutics
Modality: Small Molecules
Administration: Intravenous

Overview

DUP10 is a proprietary antitumor payload developed by DualityBio, a clinical-stage biopharmaceutical company specializing in next-generation antibody-drug conjugates (ADCs). As a key component of the DualityBio Unique Payload Antibody Conjugate (DUPAC) platform, DUP10 is designed to provide a distinct antitumor mechanism compared to other platform payloads like DUP5 and DUP9. While the specific biological target and chemical structure remain undisclosed, DUP10 is intended for integration into ADC candidates targeting various cancers and potentially autoimmune diseases, aiming to enhance therapeutic efficacy and overcome resistance mechanisms associated with conventional payloads.

Other names: DUP10DUP-10DUP 10

Beyond the preview

Go deeper on DUP10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DUP10.

Explore the full profile